Accueil › Lymphome de Burkitt › Missouri
Essais cliniques pour Lymphome de Burkitt dans Missouri
8 études pour Lymphome de Burkitt recherchent des participants dans Missouri.
Villes dans Missouri
Texte officiel de l'étude (anglais)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Mercy Hospitals and Clinics, Kansas City
- Washington University School of Medicine, St Louis
Recrutement en coursPhase 2
366 Days – 46 Years · Tous sexes · Mis à jour le 2 oct. 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- Washington University School of Medicine, St Louis
- et 3 autres
Recrutement en coursPhase 3
Âges de 18 à 39 · Tous sexes · Mis à jour le 2 oct. 2026 · NCT03150693Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- Washington University School of Medicine, St Louis
- et 4 autres
Recrutement en coursPhase 2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 29 sept. 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Mercy Hospitals and Clinics, Kansas City
- Washington University School of Medicine, St Louis
- Mercy Hospital Saint Louis, St Louis
Recrutement en coursPhase 2
365 Days · Tous sexes · Mis à jour le 25 sept. 2026 · NCT06317662Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Mercy Hospital ( Site 1024), Kansas City
Recrutement en coursPhase 1/2
6 Months – 25 Years · Tous sexes · Mis à jour le 17 sept. 2026 · NCT06395103A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Mercy Hospitals and Clinics, Kansas City
- Cardinal Glennon Children's Medical Center, St Louis
- Washington University School of Medicine, St Louis
- et 1 autres
Recrutement en coursPhase 2
Âges de 1 à 30 · Tous sexes · Mis à jour le 1 sept. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- University of Missouri Children's Hospital, Columbia
- Children's Mercy Hospitals and Clinics, Kansas City
- Cardinal Glennon Children's Medical Center, St Louis
- et 2 autres
Recrutement en coursPhase 3
365 Days – 25 Years · Tous sexes · Mis à jour le 25 août 2026 · NCT03959085The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Children's Mercy Hospital, Kansas City
Recrutement en coursPhase 2
Âges de 1 à 25 · Tous sexes · Mis à jour le 4 mai 2025 · NCT03509961Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.